Charles Sermon - 25 Jan 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
General Counsel
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
25 Jan 2024
Transactions value $
$0
Form type
4
Filing time
26 Jan 2024, 16:15:18 UTC
Previous filing
02 Jan 2024
Next filing
25 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +245K $0.00 245K 25 Jan 2024 American Depository Shares 245K $3.36 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter.
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Remarks:

Exhibit 24 - Power of Attorney